CellSearch(R) System to Be Offered at Florida Cancer Specialists

Proprietary Veridex Technology is the First Cancer Diagnostic Test to Automate and Capture Circulating Tumor Cells

RARITAN, N.J., May 7 /PRNewswire/ -- Veridex, LLC announced today that the CellSearch(R) System to measure circulating tumor cells (CTCs) will be offered at Florida Cancer Specialists (FCS), the largest privately-owned oncology and hematology practice in Florida. Veridex's CellSearch(R) test is used to predict survival in patients with metastatic breast, colorectal or prostate cancers. CellSearch(R) technology was ranked as the top medical innovation for 2009 by the Cleveland Clinic, a leading multispecialty academic medical center.

"By offering CellSearch(R) throughout our practice, Florida Cancer Specialists is fundamentally changing the way we approach cancer care as we will use CTCs to assess the prognosis of our patients," said Dr. William Harwin, Managing Partner, Florida Cancer Specialists. The CellSearch(R) System is expected to be operational at FCS by the end of May.

Through a simple blood test, the CellSearch(R) System is the first diagnostic to automate the capture and detection of tumor cells that have detached from solid tumors and entered the patient's blood. With the CellSearch(R) System, it is possible to reproducibly find a single CTC among approximately 40 billion blood cells in a 7.5 mL blood sample. The test can be used at any time during the course of disease for serial monitoring of patients with metastatic breast, colorectal or prostate cancers.

"The ability to identify a single cancer cell through our CellSearch(R) technology provides physicians with an important measure of a patient's disease prognosis to help them make more informed patient care decisions," said Ken Berlin, General Manager, Veridex. "We look forward to our partnership with FCS."

Florida Cancer Specialists is the largest privately-owned oncology and hematology practice in Florida. Florida Cancer Specialists' 64 physicians specialize in the treatment of malignancies and diseases of the blood. FCS has 26 locations and serves patients on the Gulf Coast from Clearwater to Naples.

About CellSearch(R)

The CellSearch(R) test works by using antibodies that are joined to microscopic iron particles, called ferrofluid. These antibody/ferrofluid combinations attach very specifically to CTCs. Powerful magnets then draw the CTCs out of the blood sample and they are then stained with additional bio-molecules and chemicals so that they can be positively identified as CTCs.

CellSearch(R) test results should be used in conjunction with all clinical information derived from diagnostic tests (e.g., imaging, laboratory tests), physical examination and complete medical history in accordance with appropriate patient management procedures. For further information on intended use, warnings and limitations, please refer to the CellSearch(R) CTC Test Instructions for Use, or visit www.veridex.com.

About Veridex, LLC

Veridex, LLC, a Johnson & Johnson company, is an organization dedicated to providing physicians with high-value in vitro diagnostic oncology products. Veridex's products may significantly benefit patients through earlier disease detection and may enable personalized strategies to help improve patient management and outcomes. For more information, visit www.veridex.com.

SOURCE Veridex, LLC



RELATED LINKS
http://www.veridex.com

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.